Related Experiment Video
Updated: Jun 4, 2026
09:41
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
New developments in conditioning regimens before auto-SCT in multiple myeloma.
P Moreau1, M Attal, J L Harousseau
1Hematology Department, University Hospital Hôtel-Dieu, Nantes, France. philippe.moreau@chu-nantes.fr
Bone Marrow Transplantation
|March 2, 2011
Summary
This review summarizes conditioning regimens for autologous stem cell transplant (auto-SCT) in multiple myeloma, focusing on melphalan 200 mg/m(2) and recent improvement attempts.
Area of Science:
- Hematology
- Oncology
- Clinical Therapeutics
Background:
- Autologous stem cell transplant (auto-SCT) is a cornerstone therapy for multiple myeloma.
- The standard conditioning regimen involves melphalan at 200 mg/m(2).
- Optimizing this high-dose therapy is crucial for patient outcomes.
Purpose of the Study:
- To review current knowledge on conditioning regimens for multiple myeloma.
- To explore recent advancements in high-dose therapy protocols.
- To provide a comprehensive overview of treatment strategies.
Main Methods:
- Literature review of recent studies and clinical trials.
- Analysis of conditioning regimens used in multiple myeloma treatment.
- Synthesis of data on melphalan-based and alternative regimens.
Main Results:
- Melphalan 200 mg/m(2) remains the standard conditioning agent.
- Several novel approaches are being investigated to enhance efficacy and reduce toxicity.
- Comparative data on alternative regimens are emerging.
Conclusions:
- The field of conditioning regimens for multiple myeloma is evolving.
- Further research is needed to establish superior alternative protocols.
- Personalized approaches may improve auto-SCT outcomes.
